Compare Stocks → Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ACORNASDAQ:ALNANASDAQ:AXLANASDAQ:GMDANASDAQ:JNCE Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACORAcorda Therapeutics$11.75$0.61▼$24.20$820K1.4119,299 shs416,900 shsALNAAllena Pharmaceuticals$0.07$0.06▼$1.17$37K1.1315.69 million shs96,558 shsAXLAAxcella Health$0.40-8.9%$0.84$0.34▼$41.25$1.18M0.46267,009 shs6,700 shsGMDAGamida Cell$0.02$0.25$0.03▼$2.51$2.56M0.939.20 million shs1.72 million shsJNCEJounce Therapeutics$1.88-2.6%$1.89$0.58▼$5.87$98.94M0.752.46 million shs11.60 million shs7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACORAcorda Therapeutics0.00%0.00%-95.01%-96.02%-93.88%ALNAAllena Pharmaceuticals0.00%0.00%0.00%0.00%0.00%AXLAAxcella Health0.00%0.00%0.00%0.00%-96.17%GMDAGamida Cell-8.24%+24.80%-95.99%-94.88%-99.03%JNCEJounce Therapeutics0.00%0.00%0.00%0.00%-1.05%Biden’s $374B Giveaway Into This Sector (Ad)Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right hereClick here for the full storyMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACORAcorda TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AALNAAllena PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAXLAAxcella HealthN/AN/AN/AN/AN/AN/AN/AN/AGMDAGamida Cell0.6016 of 5 stars3.42.00.00.00.00.80.0JNCEJounce TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACORAcorda TherapeuticsN/AN/AN/AN/AALNAAllena PharmaceuticalsN/AN/AN/AN/AAXLAAxcella HealthN/AN/AN/AN/AGMDAGamida Cell2.75Moderate Buy$4.7528,514.46% UpsideJNCEJounce TherapeuticsN/AN/AN/AN/ACurrent Analyst RatingsLatest AXLA, GMDA, ACOR, ALNA, and JNCE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails1/29/2024GMDAGamida CellJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Perform(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACORAcorda Therapeutics$117.63M0.00N/A0.02($127.17) per share0.00ALNAAllena PharmaceuticalsN/AN/AN/AN/A$0.23 per shareN/AAXLAAxcella HealthN/AN/AN/AN/A$1.42 per shareN/AGMDAGamida Cell$1.78M1.43N/AN/A($0.02) per share-0.83JNCEJounce Therapeutics$82M1.21N/AN/A$3.54 per share0.53Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACORAcorda Therapeutics-$252.85M-$203.83N/AN/AN/A-214.95%-2,206.93%-83.28%5/9/2024 (Estimated)ALNAAllena Pharmaceuticals-$48.66MN/A0.00N/AN/AN/A-287.46%-146.58%N/AAXLAAxcella Health-$81.19M-$19.25N/A∞N/AN/AN/A-259.91%N/AGMDAGamida Cell-$63M-$0.63N/A∞N/AN/AN/A-57.59%5/20/2024 (Estimated)JNCEJounce Therapeutics-$50.92M-$2.56N/AN/AN/AN/A-30.90%-26.31%N/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACORAcorda TherapeuticsN/AN/AN/AN/AN/AALNAAllena PharmaceuticalsN/AN/AN/AN/AN/AAXLAAxcella HealthN/AN/AN/AN/AN/AGMDAGamida CellN/AN/AN/AN/AN/AJNCEJounce TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACORAcorda Therapeutics3.070.330.26ALNAAllena PharmaceuticalsN/A1.581.58AXLAAxcella HealthN/A0.800.80GMDAGamida Cell213.142.162.09JNCEJounce TherapeuticsN/A8.378.37OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACORAcorda Therapeutics12.71%ALNAAllena Pharmaceuticals7.33%AXLAAxcella Health65.07%GMDAGamida Cell50.34%JNCEJounce Therapeutics80.66%Insider OwnershipCompanyInsider OwnershipACORAcorda Therapeutics2.60%ALNAAllena Pharmaceuticals3.70%AXLAAxcella Health2.20%GMDAGamida Cell3.40%JNCEJounce Therapeutics6.92%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableACORAcorda Therapeutics1111.24 million1.21 millionNo DataALNAAllena Pharmaceuticals35122.08 million117.57 millionNot OptionableAXLAAxcella Health112.95 million2.88 millionOptionableGMDAGamida Cell143154.05 million143.70 millionOptionableJNCEJounce Therapeutics13752.63 million48.99 millionOptionableAXLA, GMDA, ACOR, ALNA, and JNCE HeadlinesSourceHeadlineJounce Therapeutics gets grant for monoclonal antibody for treating cancer by binding PD-1pharmaceutical-technology.com - April 15 at 12:47 PMMultimatic Jounce Control Dampers Now Available For Chevy Colorado ZR2gmauthority.com - April 13 at 9:57 AM2024 Jeep Gladiator Mojave Keeps On Truckin'caranddriver.com - April 8 at 7:30 PMSan Diego VC, OrbiMed make competing buyout offers for struggling Theseusbizjournals.com - November 27 at 12:12 PMJounce Media Designates Yahoo Backstage as the Open Web's Largest MFA-Free Supply Sourcetmcnet.com - September 19 at 2:48 PMKargo Is Industry’s Only Scaled 100% Premium SSP According To Jounce Mediafinance.yahoo.com - September 18 at 2:58 PMMediavine Represents the Largest Percentage of DEI-owned Websites, Per Data from Jounce Mediatmcnet.com - September 5 at 5:55 PMBoard Member at Jounce Therapeutics Exercises Options Worth $324Kbenzinga.com - May 5 at 3:51 PMBoard Member at Jounce Therapeutics Exercises Options Worth $172Kbenzinga.com - May 4 at 7:17 PMJounce Therapeutics Director Acquires 51,400 Shares After Exercising Company Stock Optionsbenzinga.com - May 4 at 2:17 PMJounce Therapeutics Board Member Acquires 1,883,269 Shares After Exercising Company Stock Optionsbenzinga.com - May 4 at 2:17 PMJounce Therapeutics Announces Closing of Tender Offerfinance.yahoo.com - May 3 at 11:14 PMJNCE Jounce Therapeutics, Inc.seekingalpha.com - April 29 at 2:33 AMThe past five years for Jounce Therapeutics (NASDAQ:JNCE) investors has not been profitablefinance.yahoo.com - April 17 at 1:51 PMWhat is Wall Street's Target Price for Jounce Therapeutics Inc (JNCE) Stock Monday?benzinga.com - March 29 at 6:43 PMJNCE STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Jounce Therapeutics, Inc. Is Fair to Shareholdersmarkets.buffalonews.com - March 27 at 5:48 PMBuyout Offer Sends Jounce Jumping 20%msn.com - March 27 at 5:48 PMJounce Therapeutics Shares Rally on Buyout Deal >JNCEmarketwatch.com - March 27 at 12:47 PMJounce Therapeutics Agrees to Buyout, Drops Redx Deal >JNCEmarketwatch.com - March 27 at 12:47 PMJounce dumps Redx Pharma for acquisition by Concentra; to cut 84% of jobsfinance.yahoo.com - March 27 at 12:47 PMMoore Kuehn Encourages JNCE, USX, INDT, and BHWB Investors to Contact Law Firmbenzinga.com - March 23 at 9:08 PMTang Capital Partners Now Owns 10.2% of Jounce Therapeutics247wallst.com - March 17 at 7:18 PMJounce Therapeutics Announces Results from Pre-Planned Data Review of INNATE Phase 2 Trial of JTX-8064 and Pimivalimab Demonstrating Deep and Durable Responses in Platinum Resistant Ovarian Cancerfinance.yahoo.com - March 16 at 7:06 PMJounce (JNCE) Up 41% on Buyout Offer From Concentra Biosciencesfinance.yahoo.com - March 16 at 2:06 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAcorda TherapeuticsNASDAQ:ACORAcorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. The company's product pipeline includes Cimaglermin alfa (GGF2), a member of neuregulin growth factor family which is in Phase 1 clinical trials for recovery of neurological injury, as well as to enhance heart function in animal models of heart failure. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York.Allena PharmaceuticalsNASDAQ:ALNAAllena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.Axcella HealthNASDAQ:AXLAAxcella Health Inc. operates as a clinical-stage biotechnology company in the United States. The company treats complex diseases using endogenous metabolic modulators. Its product pipeline includes AXA1125 that is in Phase 2a clinical trial for long COVID therapy for patients, as well as Phase 2b clinical trial for treating non-alcoholic steatohepatitis; and AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.Gamida CellNASDAQ:GMDAGamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with hematologic malignancies, as well as in Phase II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, an investigational NK cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was incorporated in 1998 and is headquartered in Jerusalem, Israel.Jounce TherapeuticsNASDAQ:JNCEJounce Therapeutics, Inc. is a clinical stage immunotherapy company, which engages in developing treatments for cancer. It also provides novel cancer immunotherapies to attack tumors. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber, and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.